Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2020

Open Access 01-12-2020 | Hypertensive Crisis | Research

Glycopenia - induced sympathoadrenal activation in diabetes mellitus and uncontrolled arterial hypertension: an observational study

Authors: Abimbola Abobarin-Adeagbo, Andreas Wienke, Matthias Girndt, Rainer U. Pliquett

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Login to get access

Abstract

Background

Aim of this study is to investigate a possible association of hypoglycemic episodes and arterial hypertension. We hypothesize that hospitalized insulin-treated diabetes patients with hypertensive crisis have more hypoglycemic episodes than their counterparts without hypertensive crisis on admission.

Methods

In a prospective, observational cohort study, 65 insulin-treated diabetes patients (type 1, type 2, type 3c) were included in Group 1, when a hypertensive crisis was present, as control patients in Group 2 without hypertensive crisis or hypoglycemia, in Group 3, when a symptomatic hypoglycemia was present on admission. All patients were subjected to open-label continuous glucose monitoring, 24-h blood-pressure- and Holter electrocardiogram recordings, and to laboratory tests including plasma catecholamines.

Results

53 patients, thereof 19 Group-1, 19 Group-2, 15 Group-3 patients, completed this study. Group-1 patients had the highest maximum systolic blood pressure, a higher daily cumulative insulin dose at admission, a higher body-mass index, and a higher plasma norepinephrine than control patients of Group 2. Group-3 patients had more documented hypoglycemic episodes (0.8 ± 0.5 per 24 h) than Group-2 patients (0.2 ± 0.3 per 24 h), however, they were not different to the ones in Group-1 patients (0.4 ± 0.4 per 24 h). Plasma norepinephrine and mean arterial blood pressure were higher Group-1 and Group-3 patients than in control patients of Group 2. At discharge, the daily cumulative insulin dose was reduced in Group-1 (− 18.4 ± 24.9 units) and in Group-3 patients (− 18.6 ± 22.7 units), but remained unchanged in Group-2 control patients (− 2.9 ± 15.6 units).

Conclusions

An association between hypoglycemic events and uncontrolled hypertension was found in this study.
Literature
1.
go back to reference The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
2.
go back to reference The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med.2008;358:2545–59 The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med.2008;358:2545–59
3.
go back to reference Chow E, Bernjak A, Williams S, Fawdry RA, Hilbert S, Freeman J, Sheridan P, Heller S. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63:1738–47.CrossRef Chow E, Bernjak A, Williams S, Fawdry RA, Hilbert S, Freeman J, Sheridan P, Heller S. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63:1738–47.CrossRef
4.
go back to reference Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–47.CrossRef Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738–47.CrossRef
5.
go back to reference Jensen MH, Dethlefsen C, Hejlesen O, Vestergaard P. Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetol. 2020;57(5):549–58.CrossRef Jensen MH, Dethlefsen C, Hejlesen O, Vestergaard P. Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetol. 2020;57(5):549–58.CrossRef
6.
go back to reference American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020; 43(1): S66–S76 American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020; 43(1): S66–S76
7.
go back to reference Somogyi M. Exacerbation of diabetes by excess insulin action. The American Journal of Medicine. 1959;26:169–91.CrossRef Somogyi M. Exacerbation of diabetes by excess insulin action. The American Journal of Medicine. 1959;26:169–91.CrossRef
8.
go back to reference DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287:E32–41.CrossRef DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287:E32–41.CrossRef
9.
go back to reference Feldman-Billard S, Massin P, Meas T, Guillausseau PJ, Héron E. Hypoglycemia-induced blood pressure elevation in patients with diabetes. Arch Intern Med. 2010;170:829–31.CrossRef Feldman-Billard S, Massin P, Meas T, Guillausseau PJ, Héron E. Hypoglycemia-induced blood pressure elevation in patients with diabetes. Arch Intern Med. 2010;170:829–31.CrossRef
10.
go back to reference Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRef Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRef
11.
go back to reference Laborde S, Mosley E, Thayer JF. Heart rate variability and cardiac vagal tone in psychophysiological research—recommendations for experiment planning, data analysis, and data reporting. Front Psychol. 2017;8:213.CrossRef Laborde S, Mosley E, Thayer JF. Heart rate variability and cardiac vagal tone in psychophysiological research—recommendations for experiment planning, data analysis, and data reporting. Front Psychol. 2017;8:213.CrossRef
12.
go back to reference Muntzel MS, Anderson EA, Johnson AK, Mark AL. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens. 1995;17:39–50.CrossRef Muntzel MS, Anderson EA, Johnson AK, Mark AL. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens. 1995;17:39–50.CrossRef
13.
go back to reference Van De Borne P, Hausberg M, Hoffman RP, Mark AL, Anderson EA. Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol. 1999;276:R178–83. Van De Borne P, Hausberg M, Hoffman RP, Mark AL, Anderson EA. Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol. 1999;276:R178–83.
14.
go back to reference Pliquett RU, Fasshauer M, Blüher M, Paschke R. Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol. 2004;3:4.CrossRef Pliquett RU, Fasshauer M, Blüher M, Paschke R. Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol. 2004;3:4.CrossRef
15.
go back to reference Belfort-DeAguiar R, Gallezot JD, Hwang JJ, Elshafie A, Yeckel CW, Chan O, Carson RE, Ding YS, Sherwin RS. Noradrenergic activity in the human brain: a mechanism supporting the defense against hypoglycemia. J Clin Endocrinol Metab. 2018;103:2244–52.CrossRef Belfort-DeAguiar R, Gallezot JD, Hwang JJ, Elshafie A, Yeckel CW, Chan O, Carson RE, Ding YS, Sherwin RS. Noradrenergic activity in the human brain: a mechanism supporting the defense against hypoglycemia. J Clin Endocrinol Metab. 2018;103:2244–52.CrossRef
16.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.CrossRef Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.CrossRef
17.
go back to reference Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med. 1989;6:20–4.CrossRef Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med. 1989;6:20–4.CrossRef
18.
go back to reference Tang ZH, Zeng F, Li Z, Zhou L. Association and predictive value analysis for resting heart rate and diabetes mellitus on cardiovascular autonomic neuropathy in general population. J Diabetes Res. 2014;2014:215473.PubMedPubMedCentral Tang ZH, Zeng F, Li Z, Zhou L. Association and predictive value analysis for resting heart rate and diabetes mellitus on cardiovascular autonomic neuropathy in general population. J Diabetes Res. 2014;2014:215473.PubMedPubMedCentral
19.
go back to reference Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013a;4:362–72.CrossRef Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013a;4:362–72.CrossRef
20.
go back to reference Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - - causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.CrossRef Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - - causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.CrossRef
21.
go back to reference Pliquett RU, Benkhoff S, Jung O, Brandes RP. Sympathoactivation and rho-kinase-dependent baroreflex function in experimental renovascular hypertension with reduced kidney mass. BMC Physiol. 2014;14:4.CrossRef Pliquett RU, Benkhoff S, Jung O, Brandes RP. Sympathoactivation and rho-kinase-dependent baroreflex function in experimental renovascular hypertension with reduced kidney mass. BMC Physiol. 2014;14:4.CrossRef
22.
go back to reference Phan O, Burnier M, Wuerzner G. Hypertension in chronic kidney disease—role of arterial cacification and impact of treatment. Eur Cardiol. 2014;9:115–9.CrossRef Phan O, Burnier M, Wuerzner G. Hypertension in chronic kidney disease—role of arterial cacification and impact of treatment. Eur Cardiol. 2014;9:115–9.CrossRef
23.
go back to reference Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. Vital signs, QT-prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37:217–25.CrossRef Tsujimoto T, Yamamoto-Honda R, Kajio H, Kishimoto M, Noto H, Hachiya R, Kimura A, Kakei M, Noda M. Vital signs, QT-prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37:217–25.CrossRef
24.
go back to reference Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013b;4:362–72.CrossRef Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013b;4:362–72.CrossRef
25.
go back to reference Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897–904.CrossRef Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897–904.CrossRef
26.
go back to reference Hedner J, Ejnell H, Sellgren J, Hedner T, Wallin G. Is high and fluctuating muscle nerve sympathetic activity in the sleep apnoea syndrome of pathogenetic importance for the development of hypertension? J Hypertens Suppl. 1988;6:S529–31.CrossRef Hedner J, Ejnell H, Sellgren J, Hedner T, Wallin G. Is high and fluctuating muscle nerve sympathetic activity in the sleep apnoea syndrome of pathogenetic importance for the development of hypertension? J Hypertens Suppl. 1988;6:S529–31.CrossRef
27.
go back to reference Languren G, Montiel T, Ramírez-Lugo L, Balderas I, Sánchez-Chávez G, Sotres-Bayón F, Bermúdez-Rattoni F, Massieu L. Recurrent moderate hypoglycemia exacerbates oxidative damage and neuronal death leading to cognitive dysfunction after the hypoglycemic coma. J Cereb Blood Flow Metab. 2019;39:808–21.CrossRef Languren G, Montiel T, Ramírez-Lugo L, Balderas I, Sánchez-Chávez G, Sotres-Bayón F, Bermúdez-Rattoni F, Massieu L. Recurrent moderate hypoglycemia exacerbates oxidative damage and neuronal death leading to cognitive dysfunction after the hypoglycemic coma. J Cereb Blood Flow Metab. 2019;39:808–21.CrossRef
28.
go back to reference Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J. 2010;74:827–35.CrossRef Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J. 2010;74:827–35.CrossRef
29.
go back to reference Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;18:539–50.CrossRef Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;18:539–50.CrossRef
30.
go back to reference Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–94.CrossRef Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–94.CrossRef
32.
go back to reference Yan R, Li H, Kong X, Zhai X, Chen M, Sun Y, Ye L, Su X, Ma J. The accuracy and precision of the continuously stored data from flash glucose monitoring system in type 2 diabetes patients during standard meal tolerance test. Int J Endocrinol. 2020;2020:5947680.CrossRef Yan R, Li H, Kong X, Zhai X, Chen M, Sun Y, Ye L, Su X, Ma J. The accuracy and precision of the continuously stored data from flash glucose monitoring system in type 2 diabetes patients during standard meal tolerance test. Int J Endocrinol. 2020;2020:5947680.CrossRef
33.
go back to reference Fokkert M, van Dijk PR, Edens MA, Hernández AD, Slingerland R, Gans R, Álvarez ED, Bilo H. Performance of the eversense versus the free style libre flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8(1):e001193.CrossRef Fokkert M, van Dijk PR, Edens MA, Hernández AD, Slingerland R, Gans R, Álvarez ED, Bilo H. Performance of the eversense versus the free style libre flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8(1):e001193.CrossRef
34.
go back to reference Galindo RJ, Migdal AL, Davis GM, Urrutia MA, Albury B, Zambrano C, Vellanki P, Pasquel FJ, Fayfman M, Peng L, Umpierrez GE. Comparison of the FreeStyle Libre pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing (POC) in hospitalized patients with type 2 diabetes (T2D) treated with basal-bolus insulin regimen. Diabetes Care. 2020;1:192073.CrossRef Galindo RJ, Migdal AL, Davis GM, Urrutia MA, Albury B, Zambrano C, Vellanki P, Pasquel FJ, Fayfman M, Peng L, Umpierrez GE. Comparison of the FreeStyle Libre pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing (POC) in hospitalized patients with type 2 diabetes (T2D) treated with basal-bolus insulin regimen. Diabetes Care. 2020;1:192073.CrossRef
35.
go back to reference Lenzen-Schulte M. Gegen diabetes und adipositas: Dein Freund, der Ketonkörper. Deutsches Ärzteblatt. 2018;115:A1810–5. Lenzen-Schulte M. Gegen diabetes und adipositas: Dein Freund, der Ketonkörper. Deutsches Ärzteblatt. 2018;115:A1810–5.
Metadata
Title
Glycopenia - induced sympathoadrenal activation in diabetes mellitus and uncontrolled arterial hypertension: an observational study
Authors
Abimbola Abobarin-Adeagbo
Andreas Wienke
Matthias Girndt
Rainer U. Pliquett
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00613-4

Other articles of this Issue 1/2020

Diabetology & Metabolic Syndrome 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine